Medical Patent News

RSS

Biota makes major antiviral discovery

Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection.

7 Jun 2005

Biophan issued new patent for solution to enhance image quality of magnetic resonance imaging

Biophan Technologies has announced that the U.S. Patent No. 6,902,290 has been granted to the Company. The patent teaches the placement of an electronic sensor within medical devices that can offset the image artifacts that interfere with the quality of MRI imaging.

6 Jun 2005

Introgen wins European patent decision on p53 gene therapeutic

Introgen Therapeutics has announced that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's Advexin molecular therapy, were finally revoked by the EPO's Technical Board of Appeals.

3 Jun 2005

Nastech Pharmaceutical awarded new breast cancer patent

Nastech Pharmaceutical Company today announced that it has been awarded U.S. patent No. 6,894,026, entitled, "Long-acting Oxytocin Analogues for the Treatment and Prevention of Breast Cancer and Psychiatric Disorders."

31 May 2005

Targepeutics issued new U.S patent

Targepeutics has announced the issuance of U.S. Patent No. 6,884,603 for its genetically modified, mutated Interleukin 13 (IL-13) technology platform for the treatment of malignant glioma, a brain tumor (17,500 people annually; $200 million annual market).

31 May 2005

Targeted Genetics issued patent related to adeno-associated virus (AAV) technology platform

Targeted Genetics Corporation has announced the issuance of another patent related to the Company's leading adeno-associated virus (AAV) technology platform. U.S. patent #6,897,045, titled "Adeno-Associated Virus Vectors," was issued to the University of Iowa Research Foundation and is exclusively licensed to Targeted Genetics.

30 May 2005

Bioniche Life Sciences granted European patent

Bioniche Life Sciences has announced that it has had another patent granted on its core technology: Mycobacterial Cell Wall-DNA Complex (MCC). The European Patent Organization (EPO) granted the patent: - "Composition and Method for Inducing Apoptosis in Prostate Cancer Cells" (EPO1165106)

30 May 2005

Bioniche granted additional patent for mycobacterial cell wall technology

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

18 May 2005

MicroVention awarded key patent for Smart Hydrogel

MicroVention announced today that the U.S. Patent and Trademark Office has awarded the company U.S. Patent No. 6,878,384 for its proprietary environmentally-responsive or "smart" hydrogel called Intelligel.

11 May 2005

Targeted Genetics announces new patent for Hyperlipidemia

Targeted Genetics Corporation announced today issuance of U.S. patent #6,887,463, entitled, "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism."

11 May 2005

Major Chinese breakthrough for pSivida - patent granted

This first patent grant in China is important as China has the highest incidence of primary liver cancer in the world with 345,844 cases in 2002 and is a logical target market for BrachySil. The potential lower cost of the Chinese registration pathway and the vast need of BrachySil like products make China an important commercial target.

9 May 2005

Bionomics files key U.S. patents relating to cancer drug target BNO69

Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.

9 May 2005

Generex Biotechnology receives Australian patent for vaccine technology to fight cancer and pandemic influenza

Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Express is designing and testing such vaccine peptides for the control of cancer and infectious diseases with a particular focus on the pandemic H5N1 influenza, which has been reported in South East Asia.

26 Apr 2005

Maxim Pharmaceuticals issued patent for method of identifying therapeutically effective immunosupressive agents

Maxim Pharmaceuticals have announced the United States Patent and Trademark Office issued U.S. patent number 6,828,091 B2, entitled "Method of Identifying Immunosuppressive Agents."

23 Apr 2005

ARC Pharmaceuticals granted new U.S. patent

ARC Pharmaceuticals Inc. (ARC) announced today that The University of British Columbia (UBC) has been granted a new US patent entitled "Pharmaceutical Compositions and Methods Relating to Fucans, No. 6,812,220.

7 Apr 2005

Peplin has U.S. patent granted for novel anti-cancer compounds

Australian biotech Peplin Limited has announced today that the US Patent and Trademark Office had granted Peplin a patent covering the use of its macrocyclic anti-cancer compounds to stimulate the immune system.

5 Apr 2005

Glaxo's CEO must answer questions in AIDS drug patent piracy case

A California federal court has ruled that GlaxoSmithKline's (GSK) Chief Executive Officer, Jean-Pierre Garnier, must answer further questions in a deposition in a patent piracy lawsuit brought against the British drug giant over GSK's patent for AZT (Retrovir), the first AIDS drug.

4 Apr 2005

$20 billion in cardiovascular drug revenues soon subject to patent expiration

More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next three to five years, according to a report by business intelligence firm Cutting Edge Information.

30 Mar 2005

Vical Incorporated issued two Canadian patents

Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.

29 Mar 2005

Bioniche receives European patent

Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had an additional European patent granted by the European Patent Office (EPO) on its core mycobacterial cell wall technology.

29 Mar 2005